SQUAWK/NEWS
Account
Account
Menu
Live NewsCategoriesequity

Dyne Therapeutics, Inc. (DYN) News

Track canonical SquawkNews coverage tagged to DYN, Dyne Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 13 indexed stories across 8 publication days and is ordered by the same first-publication timeline used by LiveCast.

Symbol DYN Asset equity Sector Markets 90 days 13 Last 26.905 Updated Jul 30, 2026, 11:13 AM UTC Open live news feed
H RBC Reiterates DYN Outperform RBC raises DYN price target to $35 EQUITY | Jul 30, 2026, 11:13 AM UTC L DYN - Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights DYN - Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights EARNINGS | Jul 29, 2026, 08:30 PM UTC L Dyne Therapeutics receives FDA clearance to initiate DYNE-302 trial Dyne Therapeutics... REGULATION | Jul 28, 2026, 11:41 AM UTC L DYN new Overweight @ Cantor DYN new Overweight @ Cantor EQUITY | Jul 23, 2026, 12:08 PM UTC L DYN Initiated Overweight at Cantor Fitzgerald DYN Initiated Overweight at Cantor Fitzgerald EQUITY | Jul 23, 2026, 11:55 AM UTC L Today's priced deal • DYN 18.3M share Spot Secondary, priced at $20.50, by MSCO, JEFF, Evercore, LifeSci, RAJA & Jones Today's priced deal • DYN 18.3M share Spot Secondary, priced at $20.50, by MSCO, JEFF, Evercore, LifeSci, RAJA & Jones EQUITY | Jul 22, 2026, 12:59 PM UTC L DYN priced an upsized public stock offering, raising about $375M through the sale of 18.3M shares at $20.50 each, up from its initially prop DYN priced an upsized public stock offering, raising about $375M through the sale of 18.3M shares at $20.50 each, up from its initially proposed $300M raise; shares -9.5% premarket EQUITY | Jul 22, 2026, 10:30 AM UTC H Closing Bell Movers: Finward jumps after First Financial deal Stock futures were sharply higher in after-hours, adding to the session's broad gains. Traders after the close saw early reporting mostly from smaller banks, though notable names included Capital One, Bank OZK, and Pegas EARNINGS | Jul 21, 2026, 10:05 PM UTC L DYN -7% post mkt after offering headlines DYN -7% post mkt after offering headlines EQUITY | Jul 21, 2026, 08:48 PM UTC L DYN Dyne Therapeutics announces proposed public offering of common stock DYN Dyne Therapeutics announces proposed public offering of common stock EQUITY | Jul 21, 2026, 08:47 PM UTC L Dyne Therapeutics announces FDA acceptance of zeleciment rostudirsen BLA Dyne Therapeutics... REGULATION | Jul 20, 2026, 11:33 AM UTC L DYN Dyne Therapeutics announces U.S. FDA Acceptance of Biologics license application (bla) for z-rostudirsen in exon 51 duchenne muscular dy DYN Dyne Therapeutics announces U.S. FDA Acceptance of Biologics license application (bla) for z-rostudirsen in exon 51 duchenne muscular dystrophy (dmd) Dyne Therapeutics, - FDA grants priority review with pdufa date Ja REGULATION | Jul 20, 2026, 11:30 AM UTC M BDC: BUY @ Citi Citi initiates BDC with a BUY rating, among other top initiations EQUITY | Jun 26, 2026, 11:17 AM UTC